Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

ABCSG 66 / ADAPTela: First Site Activated and First Patient Enrolled

The ABCSG is pleased to announce that the first Austrian site has been activated for the ABCSG 66 / ADAPTela trial, where the first patient has also been enrolled.

The Department of Gynecology at the Medical University of Innsbruck, under the leadership of Dr. Daniel Egle, was activated for patient enrollment on August 21, 2026. This marks the official launch of the study in Austria.

ABCSG 66 / ADAPTela is a WSG-sponsored, open-label, two-arm, randomized phase III clinical trial investigating adjuvant elacestrant versus standard-of-care endocrine therapy in patients with HR-positive, HER2-negative early breast cancer at intermediate to high risk of recurrence. Both treatment arms may include a CDK4/6 inhibitor in combination with endocrine therapy.

A key focus of the study is personalized treatment selection based on genomic risk. The established Oncotype DX® test is used to determine the individual genomic risk profile of patients and to support the identification of patients who may benefit from treatment with elacestrant.

At study entry, patients have completed their standard-of-care primary treatment and should be starting endocrine therapy with or without CDK4/6 inhibitor. Patients who have already initiated this endocrine therapy may also be eligible for enrollment, provided that treatment started no more than 12 months before study entry.

A total of 1,520 patients across Germany, Spain and Austria are planned to be enrolled, including 150 patients in Austria. The Coordinating Investigator in Austria is Christoph Suppan, from the Medical University of Graz.

We congratulate Daniel Egle and his team at the Medical University of Innsbruck on this important first milestone and wish the entire study team every success with the trial.

→ Further information on the ABCSG 66 / ADAPTela study

Share on